Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with <i>BRCA1/2</i> - and Non– <i>BRCA1/2</i> -Mutant CancersTimothy A. Yap, Johann S. de Bono, Rebecca Kristeleit et al.|Cancer Discovery|2020Cited by 134
Targeting myeloid chemotaxis to reverse prostate cancer therapy resistanceChristina Guo, Johann S. de Bono, Adam Sharp et al.|Nature|2023Cited by 119
Triplet Therapy with Palbociclib, Taselisib, and Fulvestrant in <i>PIK3CA</i> -Mutant Breast Cancer and Doublet Palbociclib and Taselisib in Pathway-Mutant Solid CancersJavier Pascual, Nicholas C. Turner, Paula Proszek et al.|Cancer Discovery|2020Cited by 67
First-in-Human Study of CH5132799, an Oral Class I PI3K Inhibitor, Studying Toxicity, Pharmacokinetics, and Pharmacodynamics, in Patients with Metastatic CancerSarah P. Blagden, Udai Banerji, Aurelius Olmin et al.|Clinical Cancer Research|2014Cited by 47
Data from First-in-Human Study of CH5132799, an Oral Class I PI3K Inhibitor, Studying Toxicity, Pharmacokinetics, and Pharmacodynamics, in Patients with Metastatic CancerSarah P. Blagden, Udai Banerji, Aurelius Olmin et al.|Unknown|2023Cited by 0